BioSpace News Archive

Semeon Analytics , an ATW Tech Inc. company, is pleased to announce its most recent contract with a branch of the U.S. military to apply its technology to better understand how complex composite materials can fail and therefore facilitate the development of processes that safeguard components assembled with these new materials.

Corbin Clinical Resources, parent company of Perineologic, is a privately held medical device manufacturer. They have developed and commercialized the PrecisionPoint™ Transperineal Access System, which is the only FDA cleared, CE marked, Class ll medical device for performing freehand transperineal prostate biopsies.

C2Dx Inc., a medical device company that invests in and refines the delivery of valuable, niche products to propel their growth, has acquired the T/Pump product line from Stryker. The T/Pump is the second product line for C2Dx, joining its initial acquisition of the STIC Intra-Compartmental Pressure Monitor.

Menarini Silicon Biosystems, a pioneer of liquid biopsy and single cell technologies, announced today the launch of its innovative CellMag product line f

CyberMDX , a leading healthcare cybersecurity provider delivering visibility and threat prevention for medical devices and clinical networks, today announced that the company has been named a Representative Vendor in the Gartner 2020 Market Guide for Medical Device Security Solutions.

- binx molecular point-of-care platform poised to transform care for chlamydia and gonorrhea, the two most tested for sexually-transmitted infections -

AliveCor, the leader in AI-based personal ECG technology and provider of enterprise cardiology solutions, today announced a new collaboration with AstraZeneca

Masimo will release fourth quarter results at Conference call and webcast to begin at 1:30 p.m. PT (4:30 p.m. ET)

Baxter International Inc., a leading global medical products company, announced that its Board of Directors has declared a quarterly cash dividend of $0.245 per share of common stock.

CEL-SCI Corporation (NYSE American: CVM) today reported financial results for the quarter ended December 31, 2020, as well as key clinical and corporate developments.